Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05164094 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 6, 2026 (before its estimated October 5, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Oct 5, 2026 to Aug 18, 2027
    • Secondary endpoints: 3 to 4
    • Study sites revised (65)
    v18
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 842 to confirmed 867
    • Study sites: 67 to 65
    v17
  3. Study sites: 66 to 67v16
  4. Study sites: 65 to 66v15
  5. Phase: Phase 1 to Phase 1/2v14 Show 8 more changesShow less
    • Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 422 to 842
    • Primary and study completion dates: Jun 18, 2025 to Oct 5, 2026
    • Primary endpoints revised (4)
    • Eligibility criteria expanded, about 16 words
    • Site details revised at 65 of 65 sites
    • Study title revised
    • Study arms: 9 to 13
Show 12 earlier versionsHide 12 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 69 to 65
    v13
  2. Study sites: 63 to 69v12
  3. Enrollment target: 272 to 422v11 Show 5 more changesShow less
    • Primary and study completion dates: Jun 24, 2023 to Jun 18, 2025
    • Study sites: 42 to 63
    • Eligibility criteria expanded, about 48 words
    • Study arms: 4 to 9
    • Study title expanded, about 2 words
  4. Study sites: 41 to 42v10
  5. Study sites: 39 to 41v9
  6. Study sites: 38 to 39v8
  7. Study sites: 35 to 38v7
  8. Study sites: 34 to 35v6
  9. Study sites: 17 to 34v5
  10. Study sites: 16 to 17
    • Eligibility criteria shortened, about 20 words
    v4
  11. Study sites: 15 to 16v3
  12. Site details revised at 9 of 15 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.
Trial Details
NCT Number NCT05164094
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Epstein-Barr Virus Infection
Related terms Epstein-Barr Virus Infections, Infectious Mononucleosis
Enrollment 867 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov